3 of Wall Street’s Favorite Stocks We’re Skeptical Of

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.

Sally Beauty (SBH)

Consensus Price Target: $18.80 (21.8% implied return)

Catering to both everyday consumers as well as salon professionals, Sally Beauty (NYSE:SBH) is a retailer that sells salon-quality beauty products such as makeup and haircare products.

Why Do We Think SBH Will Underperform?

1. Dearth of new stores suggests management is prioritizing the optimization of its existing locations over growth
2. Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
3. Modest revenue base of $3.71 billion gives it less fixed cost leverage and fewer distribution channels than larger companies

Sally Beauty is trading at $15.44 per share, or 7.3x forward P/E. Read our free research report to see why you should think twice about including SBH in your portfolio.

Strategy (MSTR)

Consensus Price Target: $394.38 (170% implied return)

Once a traditional business intelligence software provider, Strategy (NASDAQ:MSTR) develops AI-powered enterprise analytics software while also functioning as a major corporate holder of Bitcoin cryptocurrency.

Why Do We Pass on MSTR?

1. MicroStrategy’s core analytics software has been eclipsed by its all-in Bitcoin strategy, leaving product innovation and enterprise deals starved for attention
2. The company’s debt-financed Bitcoin buying ties shareholder fortunes to crypto swings and interest rates, amplifying downside risk and uncertainty
3. On the bright side, its vast Bitcoin treasury gives Executive Chairman Michael Saylor a unique springboard to capture crypto upside and court investors seeking leveraged exposure to digital assets

At $146.19 per share, Strategy trades at 78.9x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MSTR.

Ocular Therapeutix (OCUL)

Consensus Price Target: $26.17 (136% implied return)

Pioneering a drug delivery platform that can eliminate the need for monthly eye injections, Ocular Therapeutix (NASDAQ:OCUL) develops sustained-release treatments for eye diseases using its proprietary ELUTYX bioresorbable hydrogel technology that gradually releases medication.

Why Do We Avoid OCUL?

1. Sales tumbled by 5.7% annually over the last two years, showing market trends are working against its favor during this cycle
2. Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 340.5 percentage points
3. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 264.1 percentage points

Ocular Therapeutix’s stock price of $11.10 implies a valuation ratio of 43.2x forward price-to-sales. To fully understand why you should be careful with OCUL, check out our full research report (it’s free).

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.